Diabetes Type 1& 2

Degludec

NICE NG28 Update Type 2 diabetes in adults: management

NICE NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Diabetes (type 1 and type 2) in children and young people: diagnosis and management

NICE NG17  Type 1 diabetes in adults: diagnosis and management

Insulin degludec (Tresiba) is available in prefilled pen devices (known as FlexTouch) in two strengths: 100 units/mL; and 200 units/mL. The 100 units/mL strength is also available in cartridge form (called Penfill). The 200 units/mL strength is higher than that of other existing basal insulin products in the UK. Ensure the correct insulin product and strength is prescribed and dispensed.

The dose-counter window of the Tresiba FlexTouch pen device shows the number of units that will be injected, irrespective of strength. Therefore no dose conversion is needed when transferring a patient from one strength of Tresiba to a different strength.

Patients should be trained on the correct use of Tresiba products, and always visually verify the dialled units on the dose counter of the prefilled pen device (irrespective of strength). Advise patients to seek medical advice immediately if they think they have administered an incorrect dose of Tresiba

MHRA Drug Safety Information April 2013

Diabetes Type 1& 2

Insulin Glargine

NICE NG28 Update Type 2 diabetes in adults: management

NICE NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management
Diabetes (type 1 and type 2) in children and young people: diagnosis and management

NICE NG17 Type 1 diabetes in adults: diagnosis and management
NICE has recommended insulin glargine as an option for people with type 1 diabetes. For people with type 2 diabetes who need to take insulin, NICE has recommended that insulin glargine should be an option only if the person: needs help with his or her insulin injections from a carer or healthcare professional, or has repeated and unpleasant hypoglycaemic episodes that significantly affect his or her way of life, or 
would otherwise need to have two insulin injections to maintain background levels every day as well as having to take other diabetes medicines orally.

Also see NYRDTC Guidance
Safety advice 2020 - lipodystrophy and cutaneous amyloidosis may occur at injection site and delay local insulin absorption. Continuous rotation of the injection site within the given injection area may help to reduce or prevent these reactions

Diabetes - Type 2

Glargine/ Lixisenatide

Non-formulary